Tech Company Financing Transactions
ValenzaBio Funding Round
ValenzaBio closed a $70 million Series A investment round on 4/12/2021. Investors included Fidelity Management & Research Company, Ikarian Capital and Janus Henderson Investors.
Transaction Overview
Company Name
Announced On
4/12/2021
Transaction Type
Venture Equity
Amount
$70,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6701 Democracy Blvd. 300
Bethesda, MD 20817
USA
Bethesda, MD 20817
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
ValenzaBio is a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting clinically-validated mechanisms of action, we seek to provide improved therapies for patients with limited treatment options.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Operating Officer
Tatyana Touzova
Chief Scientific Officer
Stephen Thomas
President
Patrick Crutcher
VP - Bus. Development
William Bonificio
VP - General Counsel
David Maizenberg
VP - Operations
Jay Mitchell
Browse more venture capital transactions:
Prev: 4/12/2021: SnackMagic venture capital transaction
Next: 4/12/2021: Mercato venture capital transaction
Share this article
News on VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs